Assenagon Asset Management S.A. Grows Position in AbbVie Inc. $ABBV

Key Points

• Assenagon Asset Management increased its AbbVie position by 55.5% in the second quarter, acquiring 748,838 additional shares and bringing its holdings to roughly $527.9 million. Institutional investors collectively own 70.23% of AbbVie.
• AbbVie exceeded quarterly expectations, reporting $3.65 in EPS and $16.99 billion in revenue, with revenue up 10.2% year over year. The company also declared a quarterly dividend of $1.73 per share, equivalent to a 2.8% annualized yield.
• Analyst sentiment remains favorable, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $275.70 versus a recent price of $243.64. However, acquisition-related financing and a reduced 2026 adjusted-EPS outlook pose risks.

Assenagon Asset Management S.A. boosted its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 55.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,097,882 shares of the company's stock after purchasing an additional 748,838 shares during the period. AbbVie makes up approximately 0.7% of Assenagon Asset Management S.A.'s investment portfolio, making the stock its 20th biggest holding. Assenagon Asset Management S.A. owned approximately 0.12% of AbbVie worth $527,911,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the business. Litman Gregory Wealth Management LLC purchased a new position in AbbVie during the 4th quarter valued at $28,000. Imprint Wealth LLC increased its stake in AbbVie by 56.2% in the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company's stock worth $29,000 after purchasing an additional 45 shares during the period. Legacy Wealth Managment LLC ID lifted its position in shares of AbbVie by 115.9% during the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company's stock worth $31,000 after purchasing an additional 73 shares during the last quarter. IFC & Insurance Marketing Inc. bought a new stake in shares of AbbVie during the fourth quarter worth $31,000. Finally, WestEnd Advisors LLC boosted its stake in shares of AbbVie by 160.4% during the fourth quarter. WestEnd Advisors LLC now owns 138 shares of the company's stock valued at $32,000 after purchasing an additional 85 shares during the period. Hedge funds and other institutional investors own 70.23% of the company's stock.

AbbVie Stock Performance

NYSE:ABBV opened at $243.64 on Friday. The company's 50-day simple moving average is $241.40 and its 200-day simple moving average is $224.82. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $267.47. The stock has a market capitalization of $430.46 billion, a P/E ratio of 68.82, a P/E/G ratio of 0.82 and a beta of 0.30.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. During the same quarter in the previous year, the business posted $2.97 EPS. AbbVie's revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, research analysts forecast that AbbVie Inc. will post 14.06 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.8%. AbbVie's dividend payout ratio is presently 195.48%.

Analyst Ratings Changes

A number of research analysts have recently commented on ABBV shares. Morgan Stanley restated an "overweight" rating and issued a $296.00 price target on shares of AbbVie in a report on Monday. Barclays boosted their price objective on shares of AbbVie from $275.00 to $300.00 and gave the company an "overweight" rating in a research report on Wednesday, July 29th. Erste Group Bank upgraded shares of AbbVie from a "hold" rating to a "buy" rating in a research note on Wednesday. Guggenheim raised their target price on shares of AbbVie from $261.00 to $288.00 and gave the stock a "buy" rating in a research report on Tuesday. Finally, Evercore set a $235.00 target price on shares of AbbVie in a research report on Friday, May 15th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $275.70.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie delivered a robust second quarter, with earnings and revenue exceeding analyst expectations. Revenue increased approximately 10% year over year, while management raised its revenue outlook and cited continued momentum from key products. ABBV Stock Dips 4% Despite Robust Q2
• Positive Sentiment: Analyst sentiment remains favorable. Erste Group Bank upgraded AbbVie from “hold” to “buy,” and Cantor Fitzgerald raised its price target to $285, suggesting potential upside from current levels. Cantor Fitzgerald Boosts AbbVie Price Target
• Positive Sentiment: AbbVie’s long-running dividend-growth record continues to support its appeal to income-focused investors, providing a potential floor for the stock despite valuation and acquisition concerns. This Stock Keeps Raising Its Dividend
• Neutral Sentiment: The Apogee acquisition is intended to expand AbbVie’s growth pipeline, but investors are assessing whether the strategic benefits will justify the transaction’s cost and integration risks. Baron Capital Exits Apogee Therapeutics
• Negative Sentiment: AbbVie reduced its 2026 adjusted EPS outlook to reflect the Apogee deal, offsetting the positive quarterly results and higher revenue guidance. The lower earnings forecast appears to be the main catalyst behind the stock’s decline. ABBV Stock Dips 4% Despite Robust Q2
• Negative Sentiment: AbbVie priced approximately $9.9 billion of senior notes to help fund the acquisition. The financing increases debt obligations and may intensify concerns about leverage, interest expense, and near-term shareholder returns. AbbVie Prices Senior Notes to Fund Acquisition

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source